Gene · 80339
Papers3,957
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 3,957
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PNPLA3 Is Associated With Hepatocellular Carcinoma, While a Five-Variant Polygenic Risk Score Shows Limited Discrimination in Korean Patients With MASLD. | J Gastroenterol Hepatol | 2026 | 42802015 | PubTator, text mining | PubMed |
| Genetic Variants Associated with Response to GLP-1 Receptor Agonists in Diabetes and Obesity. | Life (Basel) | 2026 | 42795351 | PubTator, text mining | PubMed |
| An FDA‑approved dicarboxylic acid allosterically targets PNPLA3 to resolve osteoarthritis. | Pharmacol Res | 2026 | 42790833 | PubTator, text mining | PubMed |
| Ultra-rapid progression of MAFLD to cirrhosis and post-transplant steatosis in a patient with a polygenic risk profile. | MedScience | 2026 | 42758280 | PubTator, text mining | PubMed |
| Genetic Susceptibility Versus Fibrosis Progression in North Indian Metabolic Dysfunction-Associated Steatotic Liver Disease: Distinct Roles of APOC3 and PNPLA3 in a Candidate Gene Study. | J Clin Exp Hepatol | 2026 | 42756632 | PubTator, text mining | PubMed |
| Liver Fibrosis and IRS1 rs2972146 Are Associated With Weight Loss Response After Metabolic Bariatric Surgery. | Diabetes Obes Metab | 2026 | 42755140 | PubTator, text mining | PubMed |
| Risk Factors and Definition of Younger-Onset Metabolic Dysfunction-Associated Steatotic Liver Disease Cirrhosis. | Clin Gastroenterol Hepatol | 2026 | 42749101 | PubTator, text mining | PubMed |
| Ferroptosis, immune activation and MASH-related HCC. | Gut | 2026 | 42722415 | PubTator, text mining | PubMed |
| MBOAT7 rs641738 TT genotype is associated with poorer survival in MASLD-related hepatocellular carcinoma. | Front Oncol | 2026 | 42656337 | PubTator, text mining | PubMed |
| Beyond Fat: Reframing MASLD Through Genetics, Clonal Biology, and Precision Hepatology. | Pharmaceuticals (Basel) | 2026 | 42653643 | PubTator, text mining | PubMed |
| Global landscape of clinical trials and therapeutic targets in metabolic dysfunction-associated steatotic liver disease: an integrative multi-omics analysis. | J Endocrinol Invest | 2026 | 42645756 | PubTator, text mining | PubMed |
| Spatial transcriptomics and histopathological analyses reveal potential biomarkers and immune features linked to recurrence in head and neck cancer. | Front Immunol | 2026 | 42643341 | PubTator, text mining | PubMed |
| Gene-environment interaction between heavy alcohol use and PNPLA3 rs738409 in incident cirrhosis: Evidence from a diverse U.S. cohort. | Clin Res Hepatol Gastroenterol | 2026 | 42632520 | PubTator, text mining | PubMed |
| Erratum: A PNPLA3-NACC1-RIPK3 pathway mediates macrophage necroptosis and inflammation in MASLD. | Hepatol Commun | 2026 | 42612108 | PubTator, text mining | PubMed |
| Correction to 'Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD'. | Liver Int | 2026 | 42605894 | PubTator, text mining | PubMed |
| The liver in diabetes: current state and future perspectives. | Diabetologia | 2026 | 42603840 | PubTator, text mining | PubMed |
| Rare Germline Variants in Key Pathways Contribute to Hepatocellular Carcinoma Risk in Hispanic Individuals. | Cancers (Basel) | 2026 | 42588646 | PubTator, text mining | PubMed |
| Decoding the Complexity of Hepatocellular Carcinoma: Clinical Challenges and Targeting HuR as a Novel Therapeutic Strategy. | Livers | 2026 | 42583674 | PubTator, text mining | PubMed |
| Pharmacologic management of metabolic and alcohol-associated liver disease. | Metab Target Organ Damage | 2026 | 42577825 | PubTator, text mining | PubMed |
| Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI. | Liver Int | 2026 | 42576670 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/80339/papers